Lung Kee (Bermuda) Holdings Limited Overview
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | H1 2026 |
|---|---|---|---|---|---|
| Employees (approx, year-end) | 2,900 | 2,900 | 2,900 | 2,800 | 2,700 |
The figure of 2,900 comes from the company's irasia corporate profile updated 26 June 2024. The FY2022, FY2023 and FY2025 figures come from the respective final results announcements; the H1 2026 figure comes from the 2026 interim results.
Lung Kee Group is a Hong Kong-headquartered, family-controlled precision-metal manufacturer. It is one of the world's largest makers of mould bases: the machined steel frames, plates and components that toolmakers turn into injection, die-casting and stamping moulds. The company describes itself as the leader of China's mould base industry. Its LKM brand is a de facto standard among Asian mould makers, and the company was the first in Hong Kong to bring CNC machining centres into mould base production. Plants in mainland China, Japan and Malaysia serve about 2,700 staff and thousands of tool shops. Through them, Lung Kee's demand is tied to the capital-goods cycles of consumer electronics, home appliances, automotive (including new-energy vehicles), toys, packaging and medical products. The business is single-segment, about 86% PRC-delivered, and debt-free. It holds about HK$650m of cash, and its investment case now rests on balance-sheet strength and high payouts more than on earnings, after three consecutive loss-making years.
Company's own description (latest filings)
In its FY2025 final results (20 Mar 2026) and H1 2026 interim results (21 Aug 2026), the company describes itself as principally engaged in the manufacturing and marketing of mould bases and related products. Key disclosed points:
-
It manufactures and sells directly to customers. Revenue is recognised at a point in time, when goods are delivered.
-
It grants trade credit of 30 to 90 days.
-
All contracts have an expected duration of one year or less.
-
The chief operating decision maker (the executive directors) reviews the group as one aggregated operating segment.
-
The company says its customer base is very wide, covering Asia, Europe and America. No single customer accounted for 10% or more of revenue in FY2022 through FY2025, or in H1 2025 and H1 2026.
The irasia corporate profile (updated 26 June 2024) adds:
-
The company calls itself one of the world's largest mould base manufacturers and the leader of China's mould base industry.
-
It distributes quality tool-steel brands, including DAIDO, alongside its own "LKM Special Steel".
-
Its facilities in China, Japan and Malaysia cover about 550,000 square metres.
The holding company itself provides investment holding and corporate management services. The group also holds investment properties in Hong Kong, carried at HK$146.5m at 30 June 2026.
What a mould base is and why it matters
A mould base is, in effect, a semi-finished mould. It is the precision-machined steel structure (clamping plates, cavity and core plates, ejector plates, support pillars, guide pins and bushes) into which a toolmaker machines the part-specific cavity. Mould makers increasingly outsource the base to specialist suppliers. This cuts lead times, reduces their own capital spending on heavy machining equipment, and avoids stocking raw steel. Standardised bases can be ordered from a catalogue with transparent pricing, which reduces engineering effort. Lung Kee has publicly promoted this argument, for example in a trade-press interview aimed at Vietnamese mould makers.
Business model and revenue model
| Revenue stream | Nature | Disclosure status |
|---|---|---|
| Standard mould bases | Catalogue product, made to stock or to short lead times; volume-driven | Revenue split not publicly disclosed |
| Custom-made mould bases | Made to order to customer drawings; higher machining content | — |
| High-precision interchangeable plates / precision plates | Plates machined to tight tolerances for interchangeability | — |
| Mould components and standard inserts | Guide pins, bushes, ejector components, inserts | — |
| Tool steel trading and processing | Distribution of third-party (DAIDO) and own-brand "LKM Special Steel" plastic, hot-work and cold-work steels; cut-to-size processing | — |
| Machining services | Additional machining on bases and plates. Management cited higher machining content as a driver of margin improvement in FY2025 and H1 2025 | — |
| Rental income (non-core) | Hong Kong investment properties | HK$3.2m net (FY2025); HK$1.5m (H1 2026) |
The model is about 100% product sales, with machining value-add built into product pricing. There is no subscription or licensing income. The group's economics are those of a capital-intensive, high-fixed-cost metal fabricator:
-
Raw materials and consumables (mainly mould steel) were 35.7% of revenue in FY2025.
-
Employee costs were 31.9% of revenue in FY2025.
-
Depreciation was 12.0% of revenue in FY2025.
Value-chain position
Lung Kee sits in the middle of the tooling value chain:
Upstream: special steel mills and distributors (Japanese, European and Chinese mould steel producers).
Lung Kee: turns steel into precision bases, plates and components. It also distributes tool steel, which gives it purchasing scale and lets it offer customers a "one-stop" service.
Downstream customers: independent mould and die makers, and the in-house tool rooms of manufacturers.
End markets: the products eventually moulded or die-cast with those tools.
Customer types and end-markets
| End-market | Management commentary (paraphrased, with source) |
|---|---|
| Home appliances | Weak because of China's property slump (FY2022, FY2023, FY2025); supported by trade-in subsidies (FY2025, H1 2026) |
| Household furniture products | Weak because of the property slump (FY2022, FY2023) |
| Automotive, incl. new-energy vehicles (NEV) | NEV demand a bright spot (FY2023); both NEV and traditional fuel vehicles expected to progress (FY2023 outlook) |
| Consumer and high-tech electronics | Expected recovery (FY2022 and FY2023 outlooks); hurt by US tariffs and technology controls (FY2025, H1 2026) |
| Food containers / packaging | Expected to keep growing on an environmental focus (FY2025 outlook) |
| Toys, including "trendy toys" | Growth momentum from design and branding (FY2025 outlook) |
| Medical and pandemic products | Stable in 2022; expected to shrink as the pandemic receded (FY2022 outlook) |
| AI products, robotics, "low-altitude economy" | Government-backed new growth areas (FY2025 and H1 2026 outlooks) |
Customers are mould makers rather than end-OEMs, which is why customer concentration is very low. Demand ultimately follows new-model and new-product launch activity (new moulds) in the end markets named in management commentary across FY2022 to H1 2026:
Independent characterisation
Lung Kee is a scale leader in a fragmented, commoditising niche. Its moat comes from:
-
brand recognition (LKM as a standard reference);
-
breadth of catalogue;
-
delivery speed from distributed plants;
-
steel-purchasing scale.
Its revenue fell 42% from FY2021 (HK$2,273m) to FY2025 (HK$1,320m). That decline reflects three forces:
-
the cyclical downturn in Chinese consumer-durables tooling demand;
-
export pressure from US-China trade friction and the relocation of supply chains to Southeast Asia and India;
-
price "involution" (destructive price competition) among Chinese mould base makers.
Management's response has been defensive: holding prices, raising machining content, automating to cut headcount, and cutting capex sharply. Meanwhile it has paid out cash above earnings, funded by a debt-free balance sheet. The company has made no transformational move: no acquisitions, no new segment, and no offshore production expansion has been disclosed in the last five years.
Strategy
Stated strategy themes (latest annual and interim results)
| Theme | Description (paraphrased) | First / latest mention |
|---|---|---|
| Move up the value chain | Shift toward high-quality, high-tech production; pursue orders with high machining content to gain share and revenue | FY2023 / FY2025 |
| Automation and unmanned production | Expand automated production lines and adopt unmanned technologies and equipment to reduce reliance on manpower and lift processing capability, speed and quality | FY2022 / FY2025 |
| Plastic and die-casting mould capability | Develop plastic and die-casting technology to improve processing capability, efficiency and product quality, in line with market trends (NEV die-casting, electronics) | FY2025 / H1 2026 |
| "Intelligent, advanced and efficient" production | Use smart production modes to improve overall processing capability | H1 2026 |
| Cost and raw-material discipline | Monitor raw-material prices and operating costs closely to protect margins and reduce operational risk | Every year |
| Market diversification | Strengthen the sales team; expand in the Chinese domestic market and in overseas and Southeast Asian markets; follow customers into ASEAN, India and Belt and Road markets | FY2023 / H1 2026 |
| Align with Chinese policy demand | Target sectors supported by state stimulus: trade-in programmes (appliances, autos), NEVs, high-tech electronics, smart appliances, AI/robotics, low-altitude economy | FY2023 / H1 2026 |
| Prudent finance | Keep conservative financial management and sufficient resources; no borrowings | Every year |
| Cautious stance | Adopt a cautious, pragmatic approach to manage risk and aim for sustainable development and reasonable growth | H1 2026 |
Lung Kee does not hold investor days or publish formal strategic plans. Strategy is articulated in the "Prospects" section of each results announcement. The recurring themes from FY2023 to H1 2026 are paraphrased below.
The FY2025 results close by restating the corporate ethos of "keeping abreast with time, keeping exploration and innovation", with the stated aim of returning to profit.
Strategic initiatives announced in the last 24 months (Oct 2024 – Oct 2026)
| Initiative | Status | Disclosure detail |
|---|---|---|
| Automation / unmanned machining roll-out | Ongoing | Qualitative only; no capex budget, line count or headcount target disclosed. Capex fell to HK$35.5m (FY2024) and HK$40.0m (FY2025) from HK$201m (FY2021), suggesting the main automation wave is complete |
| Machining-content upgrade (pricing and mix) | Ongoing; cited as a margin driver | Raw-material ratio improved to 35.7% (FY2025) and 34.3% (H1 2026) |
| Plastic and die-casting mould technology development | Ongoing | No investment figure disclosed |
| Cost reduction | Ongoing | Other expenses −16.6% (FY2025) and −24.2% (H1 2026); employee costs −5.9% in H1 2026; headcount −100 in H1 2026 |
| Special dividend return of capital | Executed | HK12 cents special dividend for FY2024 (HK$75.8m) |
| Share option grants (talent retention) | Executed | Options granted 27 Sep 2024; small share issuance (HK$2.84m proceeds in FY2025) |
| Governance: registrar change; board refresh | Executed | Appleby appointed Bermuda registrar (31 Dec 2024); board reduced to nine |
New business launches, partnerships, platform investments: none disclosed.
Formal ESG targets: none disclosed in the sources reviewed.
Cost programmes with quantified targets: not publicly disclosed.
Medium-term financial targets and guidance
The company provides no quantitative guidance or medium-term financial targets. Its forward-looking statements are qualitative. The H1 2026 outlook describes a harsh market outlook with multiple downside risks. The company uses profit warnings and alerts (Listing Rule 13.09 inside-information announcements) as its de facto guidance mechanism, for example on 6 Jan 2023, 5 Jan 2024, 6 Jan 2025, Jul 2025, 5 Jan 2026 and 7 Jul 2026.
Products & Services
All products sit within the single segment. Lung Kee does not publish revenue by product line, pricing or launch dates, so those fields are marked accordingly.
Product Portfolio
| Product / service | Description | Key capabilities / specifications | Target customer | Launch / latest version | Pricing model | Flagship / notes |
|---|---|---|---|---|---|---|
Standard mould bases | Catalogue mould bases in standardised sizes and configurations (plates, pillars, bushes, ejector system) | Interchangeability; short lead time; LKM catalogue standards widely adopted in China ("synonymous with domestic mould standards", per company profile) | Injection-mould makers in consumer electronics, appliances, toys and packaging | Long-standing core product; latest version not disclosed | Catalogue price lists (price transparency cited by LKM) | LKM standard series; capacity historically above 55,000 complete sets per month (trade press interview, date not specified) |
Custom-made (tailor-made) mould bases | Bases machined to customer drawings, including large and medium bases for automotive and appliance moulds | Large-size assembly; automotive-grade bases; higher machining content | Automotive, appliance and die-casting mould makers | Expanded in the 2000s (large automotive bases cited in FY2002/03) | Quote-based | Management focus on "orders with high machining content" (FY2025 outlook) |
High-precision interchangeable plates / precision plates | Plates ground and machined to tight tolerances for direct interchange | Precision grinding and CNC machining | Precision mould makers (electronics, medical) | — | Catalogue / quote | Historically produced at the Guangzhou high-precision plant (FY2003) |
Mould components | Guide pins, bushes, ejector pins and sleeves, locating parts | Standardised parts compatible with LKM bases | All mould makers | Developed at Dongguan from the early 2000s | Catalogue | Part of the "one-stop" offer |
Standard mould inserts | Pre-machined insert blocks | Standardised dimensions | Mould makers | — | Catalogue | Listed in Morningstar business description |
Tool steel: plastic mould steel | Pre-hardened and through-hardened plastic mould steels | Supplied as blocks or cut-to-size | Mould makers | Ongoing | Per-kg / per-block pricing (not disclosed) | Distribution of DAIDO (Japan); historically also ASSAB |
Tool steel: hot-work and cold-work steel | Steels for die-casting dies and stamping dies | Cut-to-size, machining | Die-casting and stamping tool makers | Ongoing | — | "LKM Special Steel" own brand |
Machining services | Additional CNC machining (cavity roughing, drilling, milling) on bases and plates | Automated and unmanned machining lines (FY2023–FY2025 outlooks) | Mould makers outsourcing machining | Rising share cited in FY2025 and H1 2025 | Quote-based | Cited as a margin driver in FY2025 |
Plastic and die-casting mould technology | Development of processing capability for plastic and die-casting moulds | Production efficiency and quality upgrades | Die-casting customers (NEV structural parts, electronics housings) | Strategic focus in FY2025 and H1 2026 outlooks | — | Management's stated technology priority |
Heat treatment, PVD coating, repair-welding (historic) | Vacuum heat treatment, PVD coating and mould repair services | Value-added services | Mould makers | Introduced in the early 2000s at Dongguan | — | Current status not re-confirmed in recent filings |
Hot runner products (historic R&D) | Hot runner systems development | Early-stage at Dongguan in 2003 | Mould makers | 2003 (development stage) | — | No mention in recent filings; status not publicly disclosed |
“—” = not publicly disclosed.
Financial Narrative
Methodology note
Lung Kee presents its income statement by nature of expense. It does not disclose cost of sales, gross profit or operating profit as separate lines. To give a consistent five-year view, the following derived measures are used. Each is computed from audited line items and is not a company-reported figure.
These derived figures include investment-property fair-value changes and other gains and losses, which are reported within pre-tax profit.
Third-party data providers compute gross margin differently. For example, S&P Global shows a FY2025 gross margin of about 61.5% using only materials as cost of revenue. Their figures are not comparable with the derived measures below.
Income statement
[Sources: FY2022 Final Results (FY2021 and FY2022 data); FY2023 Final Results; FY2025 Final Results (FY2024 and FY2025 data). Diluted EPS for FY2021 and FY2022 was not presented because there were no dilutive shares; the basic figure is shown. FY2021 YoY growth uses FY2020 revenue of about HK$2,064.9m from a secondary source (TipRanks).]
Dividend composition by year (HK cents):
-
FY2021: interim 15 + final 20
-
FY2022: interim 6 + final 6
-
FY2023: interim 5 + final 5
-
FY2024: interim 5 + final 6 + special 12
-
FY2025: interim 8 + final 12
-
FY2026 interim: 8 (declared 21 Aug 2026)
Margins
Revenue CAGR FY2021–FY2025 (four years): −12.7% per year (HK$2,273.4m to HK$1,319.9m).
Commentary: income statement trends, inflections and drivers
FY2021 peak and FY2022 collapse: FY2021 was a cyclical high. Post-COVID restocking pushed revenue up 10.1% to HK$2,273m and net profit to HK$228m. In FY2022, revenue fell 29.6% as repeated COVID lockdowns in China, a collapsing property market (which cut demand for appliances and furniture) and weaker exports shrank market orders. Management noted that the second half of 2022 was worse than the first. The raw-material ratio rose from 36.1% to 39.9%, partly because high-cost steel bought earlier turned over slowly. Net profit fell 93% to HK$15.8m. [FY2022 Final Results]
FY2023 trough: In FY2023 the company cut selling prices to win orders in a shrinking market. Revenue fell a further 9.5%, but raw-material cost fell only 0.5%, so the ratio jumped to 43.8%. Depreciation rose 6.9% after years of automation capex. The result was a HK$112.6m pre-tax loss, softened by a HK$40.2m tax credit (including HK$6.0m of prior-year overprovisions) to a HK$72.4m net loss. [FY2023 Final Results]
FY2024 partial recovery: Revenue rose 7.2% and the raw-material ratio fell back to 38.7%. The loss narrowed to HK$13.7m.
FY2025 renewed decline: Revenue fell 15.0% as aggregate orders dropped sharply. The company said it held pricing better and that machining services increased, which lowered the raw-material ratio to 35.7%, the best in five years. However, fixed costs did not fall in line:
-
employee costs were down only 1.5%;
-
PPE depreciation was down 5.6%;
-
other expenses were down 16.6%.
The net loss widened to HK$22.6m. That figure includes a HK$10.2m investment-property revaluation loss and is net of a HK$12.9m gain on disposal of PPE. [FY2025 Final Results]
The core issue is operating leverage: Employee costs have stayed at roughly HK$410–430m since FY2022 while revenue has drifted down. Employee cost rose from 25% to 32% of revenue, which absorbed all of the improvement in material margin. The derived gross margin of about 14% in FY2024 and FY2025 is roughly half the FY2021 level.
H1 2026: Revenue fell 17.5% to HK$568.3m. The raw-material ratio improved further to 34.3%. Employee costs fell 5.9% and other expenses fell 24.2%. Even so, the pre-tax loss widened to HK$14.2m, from HK$1.9m in H1 2025. An HK$9.0m PPE disposal gain and a HK$3.8m tax credit limited the net loss to HK$10.4m. [H1 2026 Interim Results]
Balance sheet
[Sources: FY2022, FY2023 and FY2025 Final Results. Book value per share uses 631.68m shares for FY2021–FY2024 and 633.89m for FY2025 (share capital HK$63.389m at HK$0.10 par).]
Latest balance sheet (30 Jun 2026):
-
Total assets HK$1,756.7m; equity HK$1,506.8m.
-
Cash HK$649.7m; no borrowings; lease liabilities HK$2.8m.
-
Inventories HK$302.1m; PPE HK$390.0m; investment properties HK$146.5m.
-
Working capital HK$914.5m.
[H1 2026 Interim Results]
Commentary. The balance sheet is extremely conservative. The group has carried no bank borrowings in every year reviewed, and cash has been placed in short-term deposits with major banks in Hong Kong and the PRC.
Equity fell by HK$720m between FY2021 and FY2025, from HK$2,271m to HK$1,551m. The drivers were:
-
cumulative dividends of about HK$662m (FY2021–FY2025 cash basis: 208.4 + 164.2 + 69.5 + 63.1 + 164.2);
-
cumulative net losses of HK$109m over FY2023–FY2025;
-
RMB translation losses of HK$136m in FY2022 and HK$44m in FY2023, partly reversed by gains of HK$61m in FY2025 and HK$42m in H1 2026.
Inventories have been run down by HK$302m since FY2022 (from HK$606.9m to HK$302.1m at June 2026), releasing cash. PPE has shrunk by 42% since FY2022 as depreciation (about HK$160m a year) far exceeds capex (about HK$35–40m a year in FY2024 and FY2025). The asset base is therefore deliberately contracting. Shareholders' funds now equal roughly HK$2.38 per share at June 2026, of which about HK$1.02 per share is net cash.
Cash flow
[Sources: Operating cash flow, capex, FCF and working capital are S&P Global Market Intelligence data via StockAnalysis.com (secondary; not cross-checked to the annual report cash flow statement). Dividends recognised as distributions per the final results notes are FY2021 HK$271.6m, FY2022 HK$164.2m, FY2023 HK$69.5m, FY2024 HK$63.2m and FY2025 HK$164.2m. The FY2021 difference from cash paid (HK$208.4m) reflects timing of payment and scrip/dividend-payable movements. Buybacks are confirmed nil by "no purchase, sale or redemption" statements in the FY2022, FY2023 and FY2025 results, and by an unchanged weighted share count of 631,677,303 in FY2021–FY2024.]
Commentary. Despite accounting losses, Lung Kee has generated strong free cash flow in FY2024 and FY2025 (HK$191m and HK$168m). The sources are a non-cash depreciation charge of about HK$160m a year, inventory liquidation of about HK$146m over those two years, and capex cut to about a quarter of FY2021 levels. This is a harvest-mode profile.
The heavy automation capex of FY2021–FY2023 (HK$497m cumulative) ended in FY2024. Those investments now feed through depreciation. FY2025 dividends (HK$164m) roughly equalled FY2025 FCF (HK$168m). FCF cannot stay at this level unless inventory release continues or EBITDA recovers.
Ratios
[Derived from audited line items as listed above. Interest coverage is not meaningful given negligible lease interest. ROIC uses an assumed 25% PRC tax rate on derived EBIT.]
Commentary on ratios.
Returns: have been negative for three years. FY2021 shows that through-cycle ROIC of mid-teens is achievable at about HK$2.2–2.3bn of revenue.
Liquidity: is outstanding: a current ratio above 5x and net cash equal to roughly 39% of equity.
Cash conversion cycle: has improved by about 40 days since FY2022, mainly because days inventory fell from 165 to 125. Raw-material inventory is still the dominant working-capital use (HK$338.6m of HK$389.4m inventory at FY2025).
DSO: of about 21 days is very low for an industrial B2B supplier. This reflects tight credit control (30–90 day terms) and a fragmented customer base. Receivables over 90 days were only HK$3.9m at FY2025.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Results by Segment and Segment Margins & Growth (%)
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Segment revenue (HKD Mn) | 1,449.3 | 1,553.2 | 1,319.9 |
Segment revenue YoY growth (%) | -9.5 | 7.2 | -15.0 |
Segment result: profit (loss) after tax (HKD Mn) | -72.4 | -13.7 | -22.6 |
Segment pre-tax result (HKD Mn) | -112.6 | -19.4 | -33.1 |
Segment pre-tax margin (%) | -7.8 | -1.2 | -2.5 |
Segment net margin (%) | -5.0 | -0.9 | -1.7 |
Contribution to group revenue (%) | 100 | 100 | 100 |
Revenue by Segment
| Metric | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|
Segment revenue (HKD Mn) | 785.2 | 688.7 | 568.3 |
Segment loss after tax (HKD Mn) | -23.9 | -3.6 | -10.4 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansGroup Entities
| Entity | Location | Function | Source |
|---|---|---|---|
Lung Kee Group Holdings Limited | Bermuda / HK | Listed holding company; corporate management | Filings |
Heyuan Longji Metal Products Co., Ltd. (河源龍記金屬製品有限公司) | Heyuan, Guangdong, PRC | Mould base manufacturing | moomoo company profile |
Lung Kee Metal Japan Co., Ltd. | Japan | Production and sales in Japan | Trade press (APMEN); moomoo |
Supervision International Co., Ltd. | — | Group subsidiary | moomoo company profile |
Lung Kee International Limited; Lung Kee Metal Limited | Hong Kong | Historic group companies in which the founders held non-voting/deferred interests (49.99%) | 2007 Interim Report |
“—” = not publicly disclosed.
Financial Analysis
| Measure | Definition |
|---|---|
Gross profit (derived) | Revenue minus "cost of inventories recognised as an expense" (inventory note) |
Material margin (derived) | Revenue minus raw materials and consumables used, adjusted for the change in finished goods and WIP |
EBIT (derived) | Pre-tax profit plus interest expense on lease liabilities (the group has no bank borrowings) |
EBITDA (derived) | EBIT plus depreciation of property, plant and equipment plus depreciation of right-of-use assets |
Income Statement and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue (HKD Mn) | 2,273.4 | 1,601.4 | 1,449.3 | 1,553.2 | 1,319.9 |
Revenue YoY growth (%) | 10.1 | -29.6 | -9.5 | 7.2 | -15.0 |
Cost of inventories expensed (HKD Mn) | 1,656.2 | 1,346.8 | 1,336.1 | 1,330.5 | 1,135.0 |
Gross profit, derived (HKD Mn) | 617.2 | 254.6 | 113.3 | 222.7 | 184.9 |
Material margin, derived (HKD Mn) | 1,451.8 | 962.9 | 814.2 | 951.7 | 848.2 |
Raw materials as % of revenue, reported (%) | 36.1 | 39.9 | 43.8 | 38.7 | 35.7 |
Employee benefits expense (HKD Mn) | 571.1 | 436.2 | 411.5 | 427.5 | 421.1 |
Other expenses (HKD Mn) | 435.6 | 369.6 | 362.2 | 383.6 | 319.8 |
Depreciation, PPE + ROU (HKD Mn) | 156.1 | 158.7 | 169.1 | 167.7 | 158.7 |
Other income, gains and losses (HKD Mn) | 39.7 | 11.7 | 25.8 | 14.4 | 27.1 |
Investment property fair-value change (HKD Mn) | -13.0 | 6.5 | -8.5 | -5.5 | -10.2 |
EBITDA, derived (HKD Mn) | 472.1 | 180.8 | 56.9 | 148.6 | 125.9 |
EBIT / operating income, derived (HKD Mn) | 315.9 | 22.0 | -112.2 | -19.1 | -32.8 |
Interest expense on leases (HKD Mn) | 0.5 | 0.4 | 0.4 | 0.3 | 0.3 |
Pre-tax profit (loss) (HKD Mn) | 315.5 | 21.7 | -112.6 | -19.4 | -33.1 |
Income tax (expense) credit (HKD Mn) | -87.6 | -5.9 | 40.2 | 5.7 | 10.5 |
Net profit (loss) attributable (HKD Mn) | 227.8 | 15.8 | -72.4 | -13.7 | -22.6 |
Basic EPS (HK cents) | 36.07 | 2.50 | -11.47 | -2.16 | -3.58 |
Diluted EPS (HK cents) | 36.07 | 2.50 | -11.47 | -2.16 | -3.58 |
Dividends per share declared for year (HK cents) | 35 | 12 | 10 | 23 | 20 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansMargin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin, derived (%) | 27.1 | 15.9 | 7.8 | 14.3 | 14.0 |
Material margin (%) | 63.9 | 60.1 | 56.2 | 61.3 | 64.3 |
EBITDA margin, derived (%) | 20.8 | 11.3 | 3.9 | 9.6 | 9.5 |
Operating (EBIT) margin, derived (%) | 13.9 | 1.4 | -7.7 | -1.2 | -2.5 |
Pre-tax margin (%) | 13.9 | 1.4 | -7.8 | -1.2 | -2.5 |
Net margin (%) | 10.0 | 1.0 | -5.0 | -0.9 | -1.7 |
Employee cost as % of revenue (%) | 25.1 | 27.2 | 28.4 | 27.5 | 31.9 |
Balance Sheet and Per-Share Data
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets (HKD Mn) | 2,745.7 | 2,301.5 | 2,093.0 | 1,971.6 | 1,817.9 |
Cash and bank balances (HKD Mn) | 833.6 | 536.6 | 428.8 | 546.6 | 588.6 |
Short-term borrowings (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Long-term borrowings (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Lease liabilities, current (HKD Mn) | 3.4 | 3.6 | 3.3 | 3.9 | 3.5 |
Lease liabilities, non-current (HKD Mn) | 5.6 | 6.0 | 3.3 | 3.9 | 0.9 |
Total debt incl. leases (HKD Mn) | 9.0 | 9.6 | 6.6 | 7.8 | 4.4 |
Net debt (negative = net cash) (HKD Mn) | -824.6 | -527.1 | -422.2 | -538.8 | -584.2 |
Total equity (HKD Mn) | 2,271.3 | 1,986.6 | 1,798.8 | 1,673.5 | 1,550.9 |
Goodwill and intangibles (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Property, plant and equipment (HKD Mn) | 668.5 | 667.7 | 656.0 | 525.2 | 440.6 |
Investment properties (HKD Mn) | 168.5 | 175.0 | 166.5 | 161.0 | 150.8 |
Inventories (HKD Mn) | 604.3 | 606.9 | 530.5 | 460.5 | 389.4 |
Trade and bills receivables, net (HKD Mn) | 159.7 | 96.0 | 95.6 | 98.7 | 75.5 |
Trade and bills payables (HKD Mn) | 57.5 | 31.4 | 35.8 | 46.1 | 29.3 |
Current assets (HKD Mn) | 1,718.4 | 1,294.1 | 1,136.4 | 1,162.5 | 1,102.4 |
Current liabilities (HKD Mn) | 341.0 | 197.7 | 193.3 | 201.5 | 179.7 |
Working capital (HKD Mn) | 1,377.4 | 1,096.4 | 943.1 | 961.0 | 922.7 |
Book value per share (HKD) | 3.60 | 3.14 | 2.85 | 2.65 | 2.45 |
Cash Flow and Margin Analysis (%)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Operating cash flow (HKD Mn) | 353.8 | 76.9 | 77.2 | 226.3 | 208.1 |
Capital expenditure (HKD Mn) | 201.3 | 182.3 | 112.9 | 35.5 | 40.0 |
Free cash flow (HKD Mn) | 152.4 | -105.5 | -35.7 | 190.8 | 168.0 |
Dividends paid (HKD Mn) | 208.4 | 164.2 | 69.5 | 63.1 | 164.2 |
Share buybacks (HKD Mn) | 0 | 0 | 0 | 0 | 0 |
Change in working capital (HKD Mn) | -29.2 | -41.9 | 25.0 | 83.1 | 93.6 |
FCF margin (%) | 6.7 | -6.6 | -2.5 | 12.3 | 12.7 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE, year-end equity (%) | 10.0 | 0.8 | -4.0 | -0.8 | -1.5 |
ROA, year-end assets (%) | 8.3 | 0.7 | -3.5 | -0.7 | -1.2 |
ROIC, NOPAT at 25% / (equity + debt − cash) (%) | 16.4 | 1.1 | -6.1 | -1.3 | -2.5 |
Current ratio (x) | 5.04 | 6.55 | 5.88 | 5.77 | 6.13 |
Debt to equity, leases only (%) | 0.4 | 0.5 | 0.4 | 0.5 | 0.3 |
Net debt / EBITDA (x) | -1.75 | -2.92 | -7.42 | -3.63 | -4.64 |
Interest coverage, EBIT / lease interest (x) | 694 | 61 | -276 | -68 | -106 |
Asset turnover, revenue / year-end assets (x) | 0.83 | 0.70 | 0.69 | 0.79 | 0.73 |
Days inventory outstanding (days) | 133.2 | 164.5 | 144.9 | 126.3 | 125.2 |
Days sales outstanding (days) | 25.6 | 21.9 | 24.1 | 23.2 | 20.9 |
Days payables outstanding (days) | 12.7 | 8.5 | 9.8 | 12.6 | 9.4 |
Cash conversion cycle (days) | 146.1 | 177.9 | 159.2 | 136.9 | 136.7 |
Dividend payout vs FCF (%) | 137 | -156 | -195 | 33 | 98 |
Revenue by Region and Revenue by Region (%)
| Region | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
The PRC revenue (HKD Mn) | 1,981.5 | 1,391.0 | 1,258.2 | 1,365.1 | 1,131.4 |
Others revenue (HKD Mn) | 291.9 | 210.4 | 191.1 | 188.1 | 188.5 |
Total revenue (HKD Mn) | 2,273.4 | 1,601.4 | 1,449.3 | 1,553.2 | 1,319.9 |
The PRC share of revenue (%) | 87.2 | 86.9 | 86.8 | 87.9 | 85.7 |
Others share of revenue (%) | 12.8 | 13.1 | 13.2 | 12.1 | 14.3 |
Region Margins & Growth (%)
| Region | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
The PRC revenue YoY growth (%) | -29.8 | -9.5 | 8.5 | -17.1 |
Others revenue YoY growth (%) | -27.9 | -9.2 | -1.6 | 0.2 |
Revenue by Region and Region Margins & Growth (%)
| Region | H1 2025 | H1 2026 |
|---|---|---|
The PRC revenue (HKD Mn) | 594.9 | 477.0 |
Others revenue (HKD Mn) | 93.8 | 91.4 |
The PRC YoY growth (%) | — | -19.8 |
Others YoY growth (%) | — | -2.6 |
Capital Markets
| Item | Value | Source |
|---|---|---|
Last price | HK$1.365 (8 Oct 2026 close) | S&P Global via StockAnalysis.com |
Shares outstanding | 634.01m | S&P Global; H1 2026 share capital |
Market capitalisation | About HK$865m | Computed |
52-week change | −2.04% to 4 Aug 2026 (price HK$1.44 then) | S&P Global via StockAnalysis.com |
Approx. 1-year price change (Oct 2025 → Oct 2026) | About +10% (HK$1.24 on 4 Oct 2025 to HK$1.365 on 8 Oct 2026), price only | moomoo (Oct 2025); StockAnalysis (Oct 2026) |
Recent trading range | Year range about HK$1.05–1.98 (to Dec 2025); HK$1.75 on 29 Dec 2025 | Google Finance |
Beta (5Y) | 0.24 | S&P Global |
Average daily volume (20 days) | About 30,000 shares (Aug 2026) | S&P Global |
Free float | About 162m shares (about 26%) | S&P Global |
Last stock split | 26 Apr 2004, 5-for-4 (1.25x) | S&P Global |
Valuation Multiples
| Multiple | Lung Kee | Basis |
|---|---|---|
P/E (TTM) | n/m (loss) | TTM net loss about HK$29.4m (FY2025 −22.6, less H1 2025 −3.6, plus H1 2026 −10.4) |
P/B | 0.57x | Equity HK$1,506.8m (30 Jun 2026) |
P/S (TTM) | 0.72x | TTM revenue about HK$1,199.5m |
Enterprise value | About HK$218m | Market cap HK$865m less net cash HK$647m (30 Jun 2026) |
EV / Sales (TTM) | 0.18x | Computed |
EV / EBITDA (TTM, derived) | About 2.0x | TTM derived EBITDA about HK$110.8m |
P / FCF (FY2025) | About 5.1x | FCF HK$168.0m |
Dividend yield (trailing 12 months paid: HK12 cents + HK8 cents) | About 14.7% | Computed |
Net cash per share | About HK$1.02 | Computed |
Per-Share Data and Dividends & Capital Returns
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Interim DPS (HK cents) | 15 | 6 | 5 | 5 | 8 |
Final DPS (HK cents) | 20 | 6 | 5 | 6 | 12 |
Special DPS (HK cents) | 0 | 0 | 0 | 12 | 0 |
Total DPS (HK cents) | 35 | 12 | 10 | 23 | 20 |
Basic EPS (HK cents) | 36.07 | 2.50 | -11.47 | -2.16 | -3.58 |
Dividends paid, cash flow (HKD Mn) | 208.4 | 164.2 | 69.5 | 63.1 | 164.2 |
Capital Markets — Moody's / S&P / Fitch ratings
| Item | Status |
|---|---|
Moody's / S&P / Fitch ratings | None (unrated) |
Debt outstanding | Nil bank borrowings; lease liabilities HK$2.8m (30 Jun 2026) |
Debt maturity profile | Not applicable; leases of HK$2.3m current and HK$0.5m non-current |
Altman Z-score | 4.26 (S&P Global; "safe" zone) |
Analyst Conclusions
Management guidance
There is no quantitative guidance. The H1 2026 interim results (21 Aug 2026) describe:
-
a harsh second-half outlook with multiple downside risks;
-
continued pressure on Chinese exports from tariffs and technology controls;
-
expected support from domestic stimulus and from the policy campaign against involutionary competition;
-
a commitment to improve production efficiency in plastic and die-casting moulds, use intelligent production, and control raw-material and operating costs;
-
a cautious and pragmatic posture.
Consensus growth expectations
Not available (no published estimates).
Analyst run-rate observation, not a forecast:
-
H1 2026 revenue of HK$568m annualises to about HK$1.14bn, below the HK$1.32bn achieved in FY2025.
-
H2 has historically been similar to or slightly below H1 (FY2025: H1 HK$689m, H2 HK$631m).
-
Unless demand improves, FY2026 revenue is likely to decline again and the group is likely to report a fourth consecutive annual loss. The H1 2026 loss of HK$10.4m already includes HK$9.0m of disposal gains.
Bull case
-
Deep value with downside protection. The stock trades at 0.57x book. Net cash of about HK$1.02 per share covers about 75% of the share price. EV is only about HK$218m against about HK$110m of TTM EBITDA and about HK$168m of FY2025 FCF.
-
Operating leverage on a recovery. The material ratio is the best in five years (34.3% in H1 2026), and employee costs are finally falling (−5.9% in H1 2026). A return to even FY2024 revenue (HK$1.55bn) on today's cost base could restore profitability. FY2021 shows 20%+ EBITDA margins at HK$2.27bn of revenue.
-
Policy tailwinds and anti-involution. Beijing's push against destructive price competition, together with NEV, AI/robotics and trade-in demand, could restore pricing power for the scale leader. Weaker private competitors without Lung Kee's cash may exit.
Bear case
-
Structural, not cyclical, decline. PRC revenue has fallen four out of five years, and the FY2024 rebound proved temporary. Export-oriented customers are moving to ASEAN and India, where Lung Kee has a limited footprint. Its "Others" revenue is flat, not growing.
-
Value-trap dynamics. Controlling-family ownership of about 74% limits activism. The company has made no buybacks despite the stock trading below net-cash-adjusted book. Dividends of HK$164m in FY2025 consumed almost all FCF, and equity has shrunk by HK$765m since FY2021 (to HK$1,507m).
-
Cash generation is partly non-repeatable. FY2024–FY2025 FCF relied on inventory liquidation (about HK$146m) and capex at about 0.25x depreciation. Once inventory normalises and maintenance capex resumes, FCF could fall toward EBITDA minus capex of about HK$60–80m on current trends, making the 20-cent dividend unsustainable.
Key catalysts and monitorables (next 12 months)
| Timing | Catalyst / monitorable |
|---|---|
| Early Jan 2027 | Possible profit warning or alert for FY2026, the de facto guidance event |
| Mar 2027 | FY2026 final results and final dividend decision, a key test of payout sustainability |
| Ongoing | Monthly China data on appliance, NEV and electronics output; trade-in programme extensions |
| Ongoing | US-China tariff negotiations; Middle East conflict and logistics costs |
| Ongoing | Evidence of PRC price recovery under anti-involution policy |
| Ongoing | Inventory level (HK$302m at June 2026) and capex trajectory |
| May 2027 | AGM: buyback mandate (watch for first use), director re-elections, board refresh (INED tenure) |
| Any time | Founder or family share dealings, or any privatisation proposal, given the discount to net assets |
Concluding analyst verdict
Lung Kee Group is a well-capitalised industry leader caught in a prolonged downturn that increasingly looks structural. Its LKM brand, scale and catalogue standards remain real assets. The company was the first in Hong Kong to put CNC machining into mould bases, it calls itself the leader of China's mould base industry, and its customer base is so fragmented that no buyer reaches 10% of sales.
None of that has protected the income statement. Revenue fell from HK$2.27bn in FY2021 to HK$1.32bn in FY2025 and is falling at a 17.5% annual pace in H1 2026. The group has lost money in each of the last three full years and in H1 2026, because a largely fixed workforce and depreciation base cannot flex down with volumes.
The balance sheet tells a very different story. With HK$650m of cash, no debt and FCF of HK$168–191m in each of the last two years, Lung Kee is valued by the market at roughly 2x trailing EBITDA on an enterprise basis and 0.57x book. Shareholders have been rewarded with a trailing yield near 15%.
The core debate is whether this is a value opportunity or a value trap. The evidence leans toward a slow-liquidating asset base: capex at a quarter of depreciation, shrinking PPE and inventory, and dividends that match FCF. That model rewards patient income investors for some time. It does not, on its own, create growth.
Re-rating would need one of three things:
-
a demand-led recovery in Chinese tooling, helped by anti-involution pricing;
-
a decisive capital allocation move, such as buybacks at a deep discount, an ASEAN or India expansion, or consolidation of weaker competitors;
-
a corporate action by the controlling family.
Absent these, we would characterise the shares as a defensive, high-yield, net-cash holding with poor earnings momentum. The main monitorables are dividend coverage and the trajectory of PRC demand.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Board of Directors
| Name | Role | Tenure on board | Background / prior roles | Education | Age (approx.) |
|---|---|---|---|---|---|
Mr. Siu Tit Lung (邵鐵龍) | Executive Director, Chairman; co-founder | Since Dec 1992 (co-founded business in 1975) | Co-founder of Lung Kee Metal; elder brother of Siu Yuk Lung; director of Pan Island Investments, Rickdee Investments and Robin Hill Investments (substantial shareholders) | — | About 76 (aged 56 per 2006 Annual Report) |
Mr. Siu Yuk Lung (邵玉龍) | Executive Director, Managing Director (chief executive role); co-founder | Since Dec 1992 | Co-founder; younger brother of the Chairman; member of the Hong Kong Mould Association; director of Pan Island, Rickdee and Robin Hill | — | About 73 (aged 53 per 2006 Annual Report) |
Mr. Wai Lung Shing (韋龍城), William | Executive Director, Finance Director and Company Secretary | Since Dec 1992 | Long-serving finance head; member of the Institute of Chartered Accountants in England & Wales and the Chinese Institute of Certified Public Accountants | MBA, University of Warwick; undergraduate studies at The Hong Kong Polytechnic University | About 65 (aged 45 per 2006 Annual Report) |
Mr. Ting Chung Ho (丁宗浩) | Executive Director | — | Operational executive | — | — |
Mr. Siu Yuk Tung, Ivan (邵旭桐) | Executive Director | — | — | — | — |
Mr. Siu Yu Hang, Leo (邵宇衡) | Executive Director | — | — | — | — |
Dr. Lee Tat Yee (李達義) | Independent Non-Executive Director; Chair of Remuneration Committee | On board since at least 2004 (listed in FY2003 Annual Report), i.e. 20+ years | Not detailed in sources reviewed | Doctorate (title "Dr."); details not disclosed | — |
Mr. Wong Hak Kun (王克勤) | Independent Non-Executive Director; Chair of Audit Committee | — | Not detailed in sources reviewed | — | — |
Ms. He Lamei (何腊梅) | Independent Non-Executive Director; Chair of Nomination Committee | — | Not detailed in sources reviewed | — | — |
“—” = not publicly disclosed.
Directors' Remuneration
| Committee | Chair | Members |
|---|---|---|
Audit Committee | Mr. Wong Hak Kun | Dr. Lee Tat Yee, Ms. He Lamei |
Remuneration Committee | Dr. Lee Tat Yee | Mr. Wong Hak Kun, Ms. He Lamei |
Nomination Committee | Ms. He Lamei | Dr. Lee Tat Yee, Mr. Wong Hak Kun |
Governance Overview
| Attribute | Status |
|---|---|
Board size | 9 (6 executive, 3 INED) |
Independence | 3 of 9 (33.3%), exactly the HKEX minimum of one-third |
Chair / CEO separation | Formally separate (Chairman Siu Tit Lung; MD Siu Yuk Lung), but held by co-founder brothers who jointly control the majority shareholder. Effective separation is limited |
Gender diversity | 1 woman of 9 directors (11%) |
Family representation | 4 of 9 directors are Siu family members |
Corporate Governance Code compliance | Company states full compliance with all code provisions of Appendix C1 for FY2023, FY2025 and H1 2026 |
INED tenure | Dr. Lee Tat Yee has served more than 20 years. HKEX's Corporate Governance Code review (concluded Dec 2024) introduces a cap on INED tenure phased in over the coming years, which may require board refreshment |
Board of Directors by Director
| Director | Role | Fees (HKD K) | Salary & benefits (HKD K) | Retirement (HKD K) | Total (HKD K) |
|---|---|---|---|---|---|
Siu Tit Lung | Chairman | 0 | 8,400 | 924 | 9,324 |
Siu Yuk Lung | Managing Director | 0 | 8,400 | 924 | 9,324 |
Wai Lung Shing | Finance Director | 0 | 2,640 | 290 | 2,930 |
Ting Chung Ho | ED | 0 | 2,569 | 283 | 2,852 |
Siu Yuk Tung, Ivan | ED | 0 | 1,920 | 211 | 2,131 |
Siu Yu Hang, Leo | ED | 0 | 1,920 | 18 | 1,938 |
Lee Tat Yee | INED | 436 | 0 | 0 | 436 |
Lee Joo Hai | INED (resigned 31 Dec 2024) | 436 | 0 | 0 | 436 |
Wong Hak Kun | INED | 452 | 0 | 0 | 452 |
He Lamei | INED | 389 | 0 | 0 | 389 |
Total board | — | 1713 | 25849 | 2650 | 30212 |
Directors' Remuneration (Annual)
| Metric | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
Total board emoluments (HKD K) | 44,754 | 47,859 | 52,464 | 30,000 | 30,212 |
Of which bonus (HKD K) | 14,900 | 18,100 | 22,700 | 1,500 | 0 |
Board & Management Changes
| Date | Change |
|---|---|
31 Dec 2024 | Resignation of INED Mr. Lee Joo Hai; board committees reconstituted; board reduced from 10 to 9 |
2023–2024 | Share options granted (about 2.43m in 2023; further grant 27 Sep 2024) |
No change | No change to Chairman, MD or Finance Director in the last five years |
Major Shareholders
| Holder | Shares | Approx. stake (%) | Nature | Source |
|---|---|---|---|---|
Pan Island Investments Limited | 366,210,937 | 57.8 | Wholly owned by a discretionary trust for Siu family members (other than the founders themselves) | Simply Wall St; FY2006/2007 reports (structure) |
David Webb (and associates) | 37,938,498 | 6.0 | Long-standing minority investor | Simply Wall St (secondary) |
Siu Tit Lung (personal, incl. joint holding with Siu Yuk Lung) | 35,851,288 | 5.65 | Founder | MarketScreener / Zonebourse, as at 30 Sep 2025 |
Siu Yuk Lung (personal, incl. joint holding) | Approx. similar to Chairman (overlapping joint holding) | — | Founder | Secondary |
Rickdee Investments Limited | — | — | Discretionary trust (family of Siu Tit Lung) | 2007 Interim Report (structure) |
Robin Hill Investments Limited | — | — | Discretionary trust (family of Siu Yuk Lung) | 2007 Interim Report (structure) |
Wai Lung Shing | 3,843,750 | 0.61 | Executive director | MarketScreener, as at 30 Jun 2025 |
Institutions (aggregate) | — | About 2.6–5.2 | Data providers differ | S&P Global / Simply Wall St |
Free float | About 162m shares | About 25.6 | Per S&P Global | StockAnalysis.com |
Competitive Landscape
Key Competitors
| # | Competitor | Country | Relevant business | Relative positioning vs Lung Kee |
|---|---|---|---|---|
| 1 | HASCO Hasenclever GmbH | Germany | Standard mould bases and components, hot runners | Premium global standard; stronger in Europe; higher price point |
| 2 | Meusburger Georg GmbH | Austria | Standard mould bases, plates, components | Premium European standard; expanding in Asia; strong e-commerce |
| 3 | DME (Hillenbrand / Milacron group) | USA | Mould bases, components, hot runners | Leading North American standard; part of a large diversified group |
| 4 | Futaba Corporation (mould & die components business) | Japan | Mould bases and die sets | Japanese standard; competes directly in Japan and with Japanese OEM tooling in China and ASEAN |
| 5 | MISUMI Group | Japan | Catalogue configurable mould and die components | Dominant in components through digital ordering; less focused on full mould bases |
| 6 | Punch Industry Co., Ltd. | Japan | Mould and die components (with China plants) | Component specialist in China and Japan |
| 7 | Progressive Components | USA | Mould components and monitoring | Niche premium components |
| 8 | Mainland Chinese mould base makers (numerous private firms in the Pearl River Delta, Ningbo/Zhejiang and Kunshan/Jiangsu clusters) | PRC | Standard and custom mould bases | Main source of price pressure; lower cost, lower brand equity |
| 9 | Taiwanese mould base makers | Taiwan / PRC | Mould bases | Compete for Taiwanese-owned factories in China |
| 10 | In-house tool rooms of large OEMs | Various | Self-supply of bases | Substitution risk |
Competitor Detail
| Metric | Lung Kee (FY2025) |
|---|---|
Revenue | HK$1,319.9m |
Revenue growth | -15.0% |
Net margin | -1.7% |
EBITDA margin (derived) | 9.5% |
Balance sheet | Net cash HK$584m; no debt |
Recent Developments
Lung Kee is a low-disclosure micro-cap. Earlier entries back to late 2024 are added for context.
Product launches, contract wins, litigation, regulatory actions and layoff announcements: none publicly announced in the period.



